CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (loss) income	$ (64,314,000)	$ 11,159,000
Adjustments to reconcile net (loss) income to cash and cash equivalents used in operating activities:
Depreciation and amortization	4,296,000	3,219,000
Amortization of debt issuance costs and debt discount	4,633,000	892,000
Goodwill impairment charges	16,867,000	0
Share-based compensation	13,731,000	21,613,000
Change in fair value of liability classified warrants	(58,000)	(445,000)
Change in fair value of liability classified earnouts	(792,000)	(53,821,000)
Change in fair value of liability classified conversion option derivatives	(2,034,000)	(15,510,000)
Realized loss on sale of investments	11,000	0
Unrealized (gain) loss on investments	(44,000)	62,000
Accretion of discount on investment securities	(712,000)	(29,000)
Deferred taxes	50,000	183,000
Gain on loan forgiveness	0	(183,000)
Credit losses	31,000	402,000
Loss on disposal of property and equipment	0	22,000
Changes in operating assets and liabilities:
Accounts receivable	(8,657,000)	(15,215,000)
Inventories	(2,913,000)	(2,584,000)
Other receivables	153,000	678,000
Prepaid expenses	2,728,000	3,545,000
Operating lease right-of-use assets	4,448,000	3,720,000
Other assets	(83,000)	(141,000)
Accrued expenses and other current liabilities	579,000	2,894,000
Income taxes payable	0	255,000
Accounts payable	3,961,000	(4,404,000)
Current and long-term operating lease liabilities	(3,909,000)	(2,998,000)
Other non-current liabilities	(394,000)	(1,073,000)
Net cash and cash equivalents used in operating activities	(32,422,000)	(47,759,000)
Cash flows from investing activities:
Purchases of property and equipment	(3,706,000)	(3,534,000)
Cash paid for practice acquisitions	(4,300,000)	(8,107,000)
Purchases of marketable securities/investments	(9,683,000)	(87,402,000)
Sales of marketable securities/investments	68,702,000	0
Net cash and cash equivalents provided by (used in) investing activities	51,013,000	(99,043,000)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	0	110,000,000
Transactions costs related to issuance of long-term debt	0	(3,663,000)
Payments made for financing of insurance payments	(3,010,000)	(3,739,000)
Payment of deferred consideration liability for acquisition	(959,000)	(509,000)
Principal payments on financing leases	(91,000)	(39,000)
Common stock repurchase	(1,019,000)	(9,000,000)
Common stock issued for options exercised	13,000	416,000
Taxes for common stock net settled	0	(413,000)
Net cash and cash equivalents provided by (used in) financing activities	(5,066,000)	93,053,000
Net increase (decrease) in cash and cash equivalents	13,525,000	(53,749,000)
Cash and cash equivalents at beginning of period	14,010,000	115,174,000
Cash and cash equivalents at end of period	27,535,000	61,425,000
Supplemental disclosure of cash flow information:
Interest and principal forgiven from Paycheck Protection Program loans	0	183,000
Cash paid for:
Income taxes	226,000	26,000
Interest	3,383,000	184,000
Supplemental disclosure of noncash investing and financing activities:
Discount of senior secured convertible note	0	28,160,000
Deferred consideration as part of practice acquisition	$ 1,813,000	$ 0